Utility of capromab pendetide (ProstaScint®) imaging in the management of prostate cancer

Techniques in Urology

Volumn 7, Issue 1, 2001, Pages 27-37

  Rosenthal, S A ^a   Haseman, M K ^a   Polascik, T J ^a  

^a Radiological Associates of Sacramento Medical Group Inc   (United States)

Author keywords

Capromab pendetide; Diagnostic imaging; Nuclear medicine; ProstaScint.; Prostate carcinoma; Radiation therapy

Indexed keywords

CAPROMAB PENDETIDE IN 111; ERYTHROCYTE TC 99M; MONOCLONAL ANTIBODY IN 111; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE;

ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SALVAGE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0035105994     PISSN: 10793259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cancer Statistics 2000
2. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
3. Prostate specific membrane antigen, a unique glutamate carboxypeptidase: A review of recent findings
4. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen
5. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer
6. Monoclonal antibodies to a new antigenic marker in epithelial cells in serum of prostatic cancer patients
7. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients
8. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
9. Five different anti prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasulature
10. Prostate-specific membrane antigen: Current and future utility
11. A phase II study of [90Y]yttrium-Capromab Pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy
12. Nuclear medicine in cancer diagnosis
13. The dual-isotope ProstaScint imaging procedure. Clinical experience and staging results in 145 patients
14. Using vascular structure for CT-SPECT registration in the pelvis
15. Immunoscintigraphy with indium-111-Capromab Pendetide: Evaluation before definitive therapy in patients with prostate cancer
16. Capromab Pendetide imaging of prostate cancer
17. Abdominal prostate cancer metastases detected with Indium In1 11 Capromab Pendetide
18. Monoclonal antibody imaging of recurrent and metastatic prostate cancer
19. Radioimmunoscintigraphy with 111-indium labeled CYT-356 for the detection of occult prostate cancer recurrence
20. 111Indium Capromab Pendetide unexpectedly localizes to renal cell carcinoma
21. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer
22. Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques
23. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy
24. Monoclonal antibody imaging of occult disease in patients with elevated PSA following definitive treatment for prostate cancer: PET and biopsy correlation
25. Comparison of helical computed tomography, positron emission tomography, and monoclonal antibody scan for the evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
26. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
27. Cancer of the prostate
28. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: Selecting the patient for adjuvant therapy
29. Radiation therapy after prostatectomy: Now or later? Semin
30. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation therapy and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy
31. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
32. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
33. Follow-up ProstaScint scans verify detection of occult soft tissue recurrence after failure of primary prostate cancer therapy
34. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients
35. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years
36. Current follow-up strategies after radical prostatectomy : A survey of American Urological Association urologists
37. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
38. Radioimmunoscintigraphy with 111-indium labeled CYT-356 for the detection of occult prostate cancer recurrence
39. Radioimmunoscintigraphy with In-111 labeled Capromab Pendetide predicts prostate cancer response to salvage radiotherapy after failed prostatectomy
40. Radiolabeled monoclonal antibody indium-111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy
41. Capromab Pendetide (ProstaScint) monoclonal antibody imaging is useful in the selection and design of treatment in patients referred for postprostatectomy radiation therapy (PPRT)
42. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer
43. Radiation therapy for a rising PSA level after radical prostatectomy
44. Postoperative radiation therapy after radical prostatectomy for prostate carcinoma
45. Role of postradical prostatectomy irradiation in carcinoma of the prostate
46. Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06
47. Feasibility and acute toxicity of radioimmunoguided prostate brachytherapy